LSE:HCM (HUTCHMED)
About HCM
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Its reportable segments include the innovation platform and commercial platform. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The commercial platform includes a prescription drugs business and a consumer health business for over-the-counter drugs.
HUTCHMED (LSE: HCM) Latest News
Investing Articles
This AIM-listed 20-bagger is the best stock I never bought
Investing Articles
Don’t worry about the State Pension! These 2 pharma stocks could make you VERY wealthy
Investing Articles
2 monster stocks in the making I’d buy for 2018
Investing Articles
This remarkable nine-bagger has further to go
Investing Articles
This forgotten growth stock deserves more attention
Investing Articles
Does cancer breakthrough make this stock a better buy than AstraZenenca plc?
Investing Articles
What are the safest places to store your money post-Brexit?
Investing Articles
Pharma fight! Should you buy GlaxoSmithKline plc, Smith & Nephew plc or Hutchison China MediTech Limited?
Investing Articles
Should You Follow Directors Buying Shares At Standard Chartered PLC, Hutchison China MediTech Limited And Britvic Plc?
Investing Articles
Could AIM Stars ASOS Plc, Telit Communications Plc And Hutchison China MediTech Limited Fund Your Retirement?
Investing Articles
3 Emerging Market Stars Set To Explode: Vodafone Group plc, PZ Cussons plc & Hutchison China Meditech Limited
Investing Articles
Are Unilever plc, Ted Baker plc, SABMiller PLC And Hutchison China MediTech Limited The Hottest Emerging Market Stocks Out There?
1❯